ANCA-Associated Vasculitis: Core Curriculum 2020

Am J Kidney Dis. 2020 Jan;75(1):124-137. doi: 10.1053/j.ajkd.2019.04.031. Epub 2019 Jul 26.

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3-ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD's Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.

Keywords: Vasculitis; anti-neutrophil cytoplasmic antibody (ANCA); autoantibody; complement; cyclophosphamide; glomerulonephritis; granulomatosis with polyangiitis (GPA); immunosuppression; microscopic polyangiitis (MPA); review; rituximab.

Publication types

  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / genetics
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / pathology
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / therapy*
  • Antibodies, Antineutrophil Cytoplasmic / immunology
  • Churg-Strauss Syndrome / genetics
  • Churg-Strauss Syndrome / immunology
  • Churg-Strauss Syndrome / pathology
  • Churg-Strauss Syndrome / therapy
  • Cyclophosphamide / therapeutic use
  • Disease Progression
  • Glomerulonephritis / genetics
  • Glomerulonephritis / immunology
  • Glomerulonephritis / pathology
  • Glomerulonephritis / therapy*
  • Glucocorticoids / therapeutic use*
  • Granulomatosis with Polyangiitis / genetics
  • Granulomatosis with Polyangiitis / immunology
  • Granulomatosis with Polyangiitis / pathology
  • Granulomatosis with Polyangiitis / therapy
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation
  • Microscopic Polyangiitis / genetics
  • Microscopic Polyangiitis / immunology
  • Microscopic Polyangiitis / pathology
  • Microscopic Polyangiitis / therapy
  • Mycophenolic Acid / therapeutic use
  • Myeloblastin / immunology
  • Peroxidase / immunology
  • Remission Induction
  • Renal Dialysis
  • Rituximab / therapeutic use

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Glucocorticoids
  • Immunosuppressive Agents
  • Rituximab
  • Cyclophosphamide
  • Peroxidase
  • Myeloblastin
  • Mycophenolic Acid